Atria Investments Inc Lowers Position in Bristol Myers Squibb Company $BMY

Atria Investments Inc decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 11.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,844 shares of the biopharmaceutical company’s stock after selling 13,959 shares during the quarter. Atria Investments Inc’s holdings in Bristol Myers Squibb were worth $4,774,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $25,000. Harbor Capital Advisors Inc. increased its stake in Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the last quarter. Total Investment Management Inc. purchased a new stake in Bristol Myers Squibb during the second quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the second quarter worth about $40,000. Finally, Mark Sheptoff Financial Planning LLC boosted its holdings in shares of Bristol Myers Squibb by 233.3% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 700 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Up 1.3%

NYSE:BMY opened at $60.64 on Friday. The firm has a market capitalization of $123.49 billion, a P/E ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company has a fifty day moving average of $55.33 and a 200 day moving average of $49.46. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. The Goldman Sachs Group restated a “neutral” rating and issued a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Leerink Partners boosted their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $66.00 price objective (up previously from $62.00) on shares of Bristol Myers Squibb in a research note on Wednesday, January 28th. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. Finally, Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price target for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Eight research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $59.20.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.